EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Role of FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in a Patient With T/Myeloid Acute Leukemia With an FLT3 Mutation

Nicholas Elias, Ahsun Siddiqui, Talal Bazzi, Daniel Lebovic

Cureus · 23.03.2026

DOI: 10.7759/cureus.105695 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cureus, erschienen am 23.03.2026. Verfasst von Nicholas Elias und 3 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Henry Ford St. John Hospital, Detroit, USA. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

flt3-itd mutationmidostaurinmixed-phenotype acute leukemia (mpal)t/myeloid leukemiatyrosine kinase inhibitor

Autor:innen und Institutionen

  • Internal Medicine, Henry Ford St. John Hospital, Detroit, USA.
  • Hematology/Oncology, Henry Ford St. John Hospital, Detroit, USA.

Zitieren

APA

Elias, N., Siddiqui, A., Bazzi, T., & Lebovic, D. (2026). Role of FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in a Patient With T/Myeloid Acute Leukemia With an FLT3 Mutation. Cureus. https://doi.org/10.7759/cureus.105695

Vancouver

Elias N, Siddiqui A, Bazzi T, Lebovic D. Role of FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in a Patient With T/Myeloid Acute Leukemia With an FLT3 Mutation. Cureus. 2026. doi:10.7759/cureus.105695

BibTeX
@article{Elias2026,
  author = {Elias, Nicholas and Siddiqui, Ahsun and Bazzi, Talal and Lebovic, Daniel},
  title = {Role of FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in a Patient With T/Myeloid Acute Leukemia With an FLT3 Mutation},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.105695}
}
Kostenlos starten →